MedTrace Logo

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

NCT06917664 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-08-27

No results posted yet for this study

Summary

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Conditions

Interventions

DRUG

sacubitril/valsartan

Sacubitril/valsartan therapy after isolated CABG

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Wei Zhao · China National Center for Cardiovascular Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-05
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917664 on ClinicalTrials.gov